Clearmind patent application for dyskinesia treatment published in Japan

Clearmind Medicine Inc. (Nasdaq: CMND) announced the publication of a patent application in Japan covering compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements.

The published application covers the use of 3-Methylmethcathinone (3-MMC) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions containing 3-MMC. The application also includes claims for combinations of 3-MMC with Palmitoylethanolamide (PEA), a compound described as having anti-inflammatory and neuroprotective properties.

The patent application is part of an ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX), through which PEA technology is integrated into Clearmind's therapeutic programs.

"The publication of the patent application in Japan strengthens our global IP position for our 3-MMC-based approach to dyskinesia, including its combination with PEA," said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind.

According to the company, its intellectual property portfolio currently consists of 19 patent families, including 32 granted patents. The information in this article is based on a press release issued by Clearmind.

You May Also Be Interested In

• Coca-Cola picks Omnicom for North America, keeps WPP globally
• Vimy Pharma closes $14.5M private placement ahead of TSXV listing
• IPM to acquire AdTech's IT business in a $2.7M two-stage deal